查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1635987

2025-2033 年肾癌治疗和诊断市场报告（按成分、癌症类型、应用和地区）

Kidney Cancer Therapeutics and Diagnostics Market Report by Component, Cancer Types, Application, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 125 Pages | 商品交期: 2-3个工作天内

价格

2024 年，全球肾癌治疗和诊断市场IMARC Group达到 54 亿美元。肾癌发病率上升、老年人口增加以及多个政府的有利倡议是推动市场发展的一些关键因素。

肾癌是一种慢性疾病，肾臟组织出现异常细胞生长，进而转变为肿瘤。其症状包括尿血、食慾不振、腰痛、疲倦、发烧、体重减轻、骨痛、高血压和贫血。肾癌可透过多种技术诊断，例如血液和尿液检查、活检、生物标记测试、电脑断层扫描(CT) 扫描、X 光、磁振造影(MRI)、膀胱镜检查和肾单位输尿管镜检查。它可以透过药物、化疗、放射治疗、肾切除术、冷冻消融、射频消融和标靶治疗来治疗。肾癌治疗和诊断有助于清除癌细胞、破坏肿瘤并防止復发，并协助医生规划治疗方案。它们还有助于改善肾功能、减少未来併发症、控制癌症扩散并提高患者舒适度。

肾癌治疗与诊断市场趋势：

由于吸烟习惯、肥胖、遗传条件和化学物质接触的日益普遍，肾癌发病率不断上升，这是推动市场成长的主要因素之一。肾癌治疗和诊断广泛用于分析和治疗肾细胞癌(RCC)、良性肾肿瘤、肾母细胞瘤、移行细胞癌、肾肉瘤、髓样癌、多房性囊性肾细胞癌以及黏液性管状细胞癌和梭形细胞癌。此外，对肾细胞癌和其他形式肾癌高度易感性的老年人口不断增加，促进了对治疗和诊断方法的需求，以控制肿瘤、延长生存期和保护肾臟的非癌症部分。此外，最近开发的能够检测生物标记的诊断工具，例如桿状病毒 IAP 重复序列 5 (BIRC5)，是早期检测透明细胞肾细胞癌和预测患者预后的关键指标，正在对市场成长产生积极影响。除此之外，引入三维 (3D) 列印来创建肾臟及其肿瘤的术前模型，从而帮助医生製定治疗计划并为患者提供适当的咨询，减少手术错误，增强效率和保留大部分肾功能有利于市场成长。此外，政府实施的各种旨在传播癌症意识的措施正在为市场创造积极的前景。预计其他因素包括医疗保健行业的显着增长、为确定潜在治疗方案而对研发 (R&D) 活动的投资不断增加，以及机器人手术、远距医疗和人工智慧 (AI) 等先进技术的广泛采用以进一步推动市场成长。

本报告回答的关键问题：

  • 迄今为止，全球肾癌治疗和诊断市场的表现如何，未来几年将如何表现？
  • 全球肾癌治疗和诊断市场的驱动因素、限制因素和机会是什么？
  • 主要区域市场有哪些？
  • 哪些国家代表了最具吸引力的肾癌治疗和诊断市场？
  • 基于组件的市场区隔是什么？
  • 根据癌症类型分類的市场是怎么样的？
  • 基于应用程式的市场区隔是什么？
  • 全球肾癌治疗与诊断市场的竞争结构如何？
  • 谁是全球肾癌治疗和诊断市场的主要参与者/公司？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球肾癌治疗与诊断市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：按组成部分

  • 药品
    • 市场趋势
    • 关键环节
      • 药品：依治疗类别
        • 标靶治疗
        • 免疫疗法
        • 其他的
      • 药品：依药理分类
        • 血管新生抑制剂
        • mTOR抑制剂
        • 单株抗体
        • 细胞激素免疫治疗（II-2）
    • 市场预测
  • 诊断
    • 市场趋势
    • 关键环节
      • 影像学检查
      • 活检
      • 验血
      • 其他的
    • 市场预测

第 7 章：市场区隔：按癌症类型

  • 透明细胞肾细胞癌
    • 市场趋势
    • 市场预测
  • 乳头状肾细胞癌
    • 市场趋势
    • 市场预测
  • 嫌色肾细胞癌
    • 市场趋势
    • 市场预测
  • 移行细胞癌
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：按应用

  • 医院
    • 市场趋势
    • 市场预测
  • 製药实验室
    • 市场趋势
    • 市场预测
  • 基因组实验室
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：驱动因素、限制与机会

  • 概述
  • 司机
  • 限制
  • 机会

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Bristol-Myers Squibb Company
    • Exelixis Inc.
    • Genentech Inc. (Roche Holding AG)
    • Novartis AG
    • Pfizer Inc.
Product Code: SR112025A7528

The global kidney cancer therapeutics and diagnostics market size reached USD 5.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 9.2 Billion by 2033, exhibiting a growth rate (CAGR) of 5.9% during 2025-2033. The rising incidences of kidney cancer, increasing geriatric population, and favorable initiatives by several governments represent some of the key factors driving the market.

Kidney cancer is a chronic disease where abnormal cell growth occurs in kidney tissues, which turns into tumors. Its symptoms include blood in urine, loss of appetite, flank pain, tiredness, fever, weight loss, bone pain, high blood pressure, and anemia. Kidney cancer is diagnosed through various techniques, such as blood and urine tests, biopsy, biomarker testing, computed tomography (CT) scan, X-ray, magnetic resonance imaging (MRI), cystoscopy, and nephron-ureteroscopy. It can be treated through medications, chemotherapy, radiation therapy, nephrectomy, cryoablation, radiofrequency ablation, and targeted therapy. Kidney cancer therapeutics and diagnostics aid in the removal of cancer cells, destroy tumors and prevent recurring, and assist physicians in planning treatments. They also help in improving kidney function, reducing future complications, controlling cancer spread, and enhancing patient comfort.

Kidney Cancer Therapeutics and Diagnostics Market Trends:

The rising incidences of kidney cancer due to the increasing prevalence of smoking habits, obesity, genetic conditions, and exposure to chemicals is one of the primary factors driving the market growth. Kidney cancer therapeutics and diagnostics are widely used to analyze and treat renal cell carcinoma (RCC), benign kidney tumors, Wilms tumors, transitional cell cancer, renal sarcoma, medullary carcinoma, multilocular cystic RCC, and mucinous tubular and spindle cell carcinoma. Furthermore, the rising geriatric population with high susceptibility to renal cell carcinoma and other forms of kidney cancer is facilitating the demand for therapeutics and diagnostics to manage tumors, prolong survival, and preserve noncancerous parts of the kidney. Additionally, the recent development of diagnostic tools capable of detecting biomarkers, such as baculoviral IAP repeat containing 5 (BIRC5), a key indicator for early detection of clear cell RCC and predicting patient prognosis, is positively influencing the market growth. Apart from this, the introduction of three-dimensional (3D) printing to create pre-operative models of the kidney and its tumors, which, in turn, aids physicians in treatment planning and providing appropriate counseling to the patients, reducing surgical errors, enhancing efficiency, and preserving the majority of kidney functions are favoring the market growth. Moreover, the implementation of various government initiatives to spread awareness regarding cancer is creating a positive outlook for the market. Other factors, including significant growth in the healthcare industry, rising investment in research and development (R&D) activities to identify potential treatment options, and widespread adoption of advanced technologies, such as robotic surgery, telemedicine, and artificial intelligence (AI), are anticipated to drive the market growth further.

Key Market Segmentation:

Component Insights:

  • Drugs
  • Drugs by Therapeutic Class
  • Targeted Therapy
  • Immunotherapy
  • Others
  • Drugs by Pharmacologic Class
  • Angiogenesis Inhibitors
  • mTOR Inhibitors
  • Monoclonal Antibodies
  • Cytokine Immunotherapy (II-2)
  • Diagnostics
  • Imaging Test
  • Biopsy
  • Blood Test
  • Others
  • The report has also provided a detailed breakup and analysis of the kidney cancer therapeutics and diagnostics market based on the component. This includes drugs (therapeutic class (targeted therapy, immunotherapy, and others) and pharmacological class (angiogenesis inhibitors, mTOR inhibitors, monoclonal antibodies, and cytokine immunotherapy (II-2) and diagnostics (imaging test, biopsy, blood test, and others). According to the report, drugs represented the largest segment.

Cancer Types Insights:

  • Clear Cell RCC
  • Papillary RCC
  • Chromophobe RCC
  • Transitional Cell Carcinoma
  • Others

Application Insights:

  • Hospitals
  • Pharmaceutical Labs
  • Genomic Laboratories
  • Others

Regional Insights:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for kidney cancer therapeutics and diagnostics. Some of the factors driving the North America kidney cancer therapeutics and diagnostics market include increasing incidences of kidney cancer, rising research and development (R&D) expenditure, increasing geriatric population, etc.

Competitive Landscape:

  • The report has also provided a comprehensive analysis of the competitive landscape in the global kidney cancer therapeutics and diagnostics market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Bristol-Myers Squibb Company, Exelixis Inc., Genentech Inc. (Roche Holding AG), Novartis AG, Pfizer Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global kidney cancer therapeutics and diagnostics market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global kidney cancer therapeutics and diagnostics market?
  • What are the key regional markets?
  • Which countries represent the most attractive kidney cancer therapeutics and diagnostics markets?
  • What is the breakup of the market based on the component?
  • What is the breakup of the market based on the cancer types?
  • What is the breakup of the market based on the application?
  • What is the competitive structure of the global kidney cancer therapeutics and diagnostics market?
  • Who are the key players/companies in the global kidney cancer therapeutics and diagnostics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Kidney Cancer Therapeutics and Diagnostics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Component

  • 6.1 Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Drugs by Therapeutic Class
        • 6.1.2.1.1 Targeted Therapy
        • 6.1.2.1.2 Immunotherapy
        • 6.1.2.1.3 Others
      • 6.1.2.2 Drugs by Pharmacologic Class
        • 6.1.2.2.1 Angiogenesis Inhibitors
        • 6.1.2.2.2 mTOR Inhibitors
        • 6.1.2.2.3 Monoclonal Antibodies
        • 6.1.2.2.4 Cytokine Immunotherapy (II-2)
    • 6.1.3 Market Forecast
  • 6.2 Diagnostics
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Imaging Test
      • 6.2.2.2 Biopsy
      • 6.2.2.3 Blood Test
      • 6.2.2.4 Others
    • 6.2.3 Market Forecast

7 Market Breakup by Cancer Types

  • 7.1 Clear Cell RCC
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Papillary RCC
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Chromophobe RCC
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Transitional Cell Carcinoma
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Pharmaceutical Labs
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Genomics Laboratories
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Bristol-Myers Squibb Company
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Exelixis Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Genentech Inc. (Roche Holding AG)
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 SWOT Analysis
    • 14.3.4 Novartis AG
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Pfizer Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: Kidney Cancer Therapeutics and Diagnostics Market: Major Drivers and Challenges
  • Figure 2: Global: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Kidney Cancer Therapeutics and Diagnostics Market: Breakup by Component (in %), 2024
  • Figure 5: Global: Kidney Cancer Therapeutics and Diagnostics Market: Breakup by Cancer Types (in %), 2024
  • Figure 6: Global: Kidney Cancer Therapeutics and Diagnostics Market: Breakup by Application (in %), 2024
  • Figure 7: Global: Kidney Cancer Therapeutics and Diagnostics Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Kidney Cancer Therapeutics and Diagnostics (Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Kidney Cancer Therapeutics and Diagnostics (Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Kidney Cancer Therapeutics and Diagnostics (Diagnostics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Kidney Cancer Therapeutics and Diagnostics (Diagnostics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Kidney Cancer Therapeutics and Diagnostics (Clear Cell RCC) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Kidney Cancer Therapeutics and Diagnostics (Clear Cell RCC) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Kidney Cancer Therapeutics and Diagnostics (Papillary RCC) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Kidney Cancer Therapeutics and Diagnostics (Papillary RCC) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Kidney Cancer Therapeutics and Diagnostics (Chromophobe RCC) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Kidney Cancer Therapeutics and Diagnostics (Chromophobe RCC) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Kidney Cancer Therapeutics and Diagnostics (Transitional Cell Carcinoma) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Kidney Cancer Therapeutics and Diagnostics (Transitional Cell Carcinoma) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Kidney Cancer Therapeutics and Diagnostics (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Kidney Cancer Therapeutics and Diagnostics (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Kidney Cancer Therapeutics and Diagnostics (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Kidney Cancer Therapeutics and Diagnostics (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Kidney Cancer Therapeutics and Diagnostics (Pharmaceutical Labs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Kidney Cancer Therapeutics and Diagnostics (Pharmaceutical Labs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Kidney Cancer Therapeutics and Diagnostics (Genomics Laboratories) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Kidney Cancer Therapeutics and Diagnostics (Genomics Laboratories) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Kidney Cancer Therapeutics and Diagnostics (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Kidney Cancer Therapeutics and Diagnostics (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: North America: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: North America: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: United States: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: United States: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Canada: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Canada: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Asia-Pacific: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Asia-Pacific: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: China: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: China: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Japan: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Japan: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: India: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: India: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: South Korea: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: South Korea: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Australia: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Australia: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Indonesia: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Indonesia: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Others: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Others: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Europe: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Europe: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Germany: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Germany: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: France: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: France: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: United Kingdom: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: United Kingdom: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Italy: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Italy: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Spain: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Spain: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Russia: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Russia: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Others: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Others: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Latin America: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Latin America: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Brazil: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Brazil: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Mexico: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Mexico: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Others: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Others: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Middle East and Africa: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Middle East and Africa: Kidney Cancer Therapeutics and Diagnostics Market: Breakup by Country (in %), 2024
  • Figure 78: Middle East and Africa: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Global: Kidney Cancer Therapeutics and Diagnostics Industry: Drivers, Restraints, and Opportunities
  • Figure 80: Global: Kidney Cancer Therapeutics and Diagnostics Industry: Value Chain Analysis
  • Figure 81: Global: Kidney Cancer Therapeutics and Diagnostics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Kidney Cancer Therapeutics and Diagnostics Market: Key Industry Highlights, 2024 & 2033
  • Table 2: Global: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Breakup by Component (in Million USD), 2025-2033
  • Table 3: Global: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Breakup by Cancer Types (in Million USD), 2025-2033
  • Table 4: Global: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 5: Global: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Kidney Cancer Therapeutics and Diagnostics Market: Competitive Structure
  • Table 7: Global: Kidney Cancer Therapeutics and Diagnostics Market: Key Players